文献速递肿瘤 PET/CT核素与放射性配体治疗

68Ga-PSMA-11 PET/CT 提高肝细胞癌肿瘤检出并影响管理

68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma.
PubMed 文献 · J Nucl Med · 2021-01-28

该回顾性研究纳入40例肝细胞癌患者,比较68Ga-PSMA-11 PET/CT与多期增强CT在分期、预后分组及管理决策上的影响。PET对肝外病灶灵敏度为6/6(100%)而CT为4/6(67%),PET使20%患者上调分期、47.5%患者管理改变,约半数管理变化者因检出远处转移而转为系统治疗。

要点

  • 68Ga-PSMA-11 PET/CT对肝外病灶检出灵敏度高于CT(100% vs 67%)。
  • PET使20%患者上调分期、5%下调分期,47.5%患者管理计划改变。
  • 管理改变者中47.4%检出远处转移并归为IV期,多数转为系统治疗。

核心结论

  • 68Ga-PSMA-11 PET/CT对肝细胞癌转移灶的检出准确性高于CT,并与约半数患者的管理改变相关。

研究设计与样本

  • 回顾性纳入2018年9月至2019年9月间接受68Ga-PSMA-11 PET/CT分期的40例肝细胞癌患者。
  • 由3名设盲读者分别按患者和区域评估PET/CT与多期增强CT,病灶经随访影像或组织病理学验证。
  • 通过标准化调查评估PET扫描前后的管理方案,并记录无进展生存期。

主要发现

  • 中位年龄65岁(范围37-81岁),中位Child-Pugh评分5分(范围5-9分),67.5%(27/40)患者为初治。
  • 在有病灶验证的患者中,PET与CT检出肝脏病灶的灵敏度均为31/32(97%),肝外病灶灵敏度分别为6/6(100%)与4/6(67%)。
  • PET与CT在肝脏水平的阳性预测值均为100%。
  • PET与CT分期一致者30/40(75%),PET上调分期8/40(20%)、下调分期2/40(5%)。
  • 管理计划改变者19/40(47.5%),其中9/19(47.4%)检出远处转移并归为IV期,8/9(89%)转为系统治疗,2例接受177Lu-PSMA-617放射配体治疗。

临床怎么用

  • 对于肝细胞癌分期,68Ga-PSMA-11 PET/CT可较CT更灵敏地检出肝外转移,有助于识别适合系统治疗的患者。

局限性

  • 样本量较小(40例)且为回顾性设计,管理改变通过标准化调查评估,可能存在偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatocellular carcinoma (HCC) is the sixth most prevalent cancer and the third most frequent cause of cancer-related death. A growing number of local and systemic therapies are available, and accurate staging is critical for management decisions. We assessed the impact of neovasculature imaging by 68Ga-PSMA-11 PET/CT on disease staging, prognostic groups, and management of patients with HCC compared with staging with CT. Methods: Forty patients who received imaging with 68Ga-PSMA-11 PET/CT for HCC staging between September 2018 and September 2019 were retrospectively included. Management before and after PET scanning was assessed by standardized surveys. The presence of HCC was evaluated by 3 masked readers on a per-patient and per-region basis for PET/CT (PET criteria) and multiphase contrast-enhanced CT (CT criteria) in separate sessions. Lesions were validated by follow-up imaging or histopathology, and progression-free survival was recorded. Endpoints were detection rate and positive predictive value for 68Ga-PSMA-11 PET versus CT, interreader reproducibility, and changes in stage, prognostic groups, and management plans. Results: Median age was 65 y (range, 37-81 y), and median Child-Pugh score was 5 (range, 5-9). Most patients were treatment-naïve (27/40, 67.5%). The sensitivity of PET versus CT to identify liver lesions for patients with lesion validation was 31 of 32 (97%) for both modalities, whereas it was 6 of 6 (100%) versus 4 of 6 (67%), respectively, for extrahepatic lesions. PET and CT each had a positive predictive value of 100% at the liver level. PET versus CT stage was congruent in 30 of 40 (75%) patients; upstaging was seen in 8 of 40 patients (20%), whereas 2 of 40 (5%) had downstaging by PET. Intended management changed in 19 of 40 patients (47.5%); 9 of 19 of these patients were found to have detectable distant metastases (47.4%) and assigned stage 4 disease, most of whom were shifted to systemic therapy (8/9, 89%). Two patients underwent 177Lu-PSMA-617 radioligand therapy. Median progression-free survival was 5.2 mo for the entire cohort; 5.3 mo for PET M0, and 4.7 mo for PET M1 patients, respectively. Conclusion:68Ga-PSMA-11 PET demonstrated higher accuracy than CT in the detection of HCC metastases and was associated with a management change in about half the patient cohort.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Hirmas N, Leyh C, Sraieb M, et al. 68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma. J Nucl Med. 2021. PMID: 33509970. doi:10.2967/jnumed.120.257915

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。